hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 17:35:28 - browse：491

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Making AI in medicine accessible to smaller, and rural hospitals

WSS

Researchers explore possible ties between long Covid, menopause

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Brain worms: The science behind RFK Jr.'s parasitic infection

First recipient of genetically engineered pig kidney has died

Beam Therapeutics to lay off 20% of its staff, re

How to improve immunocompromised access to mAb treatments

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lawmakers consider Medicare pay reforms for doctors

Anesthesiologist group: stop taking Ozempic before surgery

STAT Readout Newsletter: Today's biggest biotech updates

Drug repurposing or repositioning? The language matters

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Medical records are filled with copy

First Opinion Podcast: Long Covid needs a new approach

At least 13 dead in Texas as scorching temps continue

H5N1 bird flu: what we're starting to learn about infection in cows

explore

FDA gives detailed accounting of AI

STAT Summit: How a Chicago ER doctor tackles gun violence

Lawmakers consider Medicare pay reforms for doctors

Readout LOUD podcast: What to know about H5N1 bird flu

FDA gives detailed accounting of AI

STAT Readout Newsletter: Today's biggest biotech updates

focus

entertainment

focus

explore